8:45 – 10:50 A.M.

EVIDENCE

 

Moderator: Roger Klein, Director, Molecular Oncology Laboratory at BloodCenter of Wisconsin and Clinical Assistant Professor of Pathology at the Medical College of Wisconsin

8:45 – 9:05 A.M.

FDA Perspective

 

Robert L. Becker, Jr., Chief Medical Officer for the Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, U.S. Food and Drug Administration

9:05 – 9:25 A.M.

Payer Perspective

 

Margaret Piper, Director of Genomics Resources for the Blue Cross and Blue Shield Technology Evaluation Center

9:25 – 9:45 A.M.

Evidence-Based Review Group Perspective

 

Ned Calonge, President and CEO of the Colorado Trust

9:45 – 10:05 A.M.

Health-Care Provider Perspective

 

Dan Hayes, Clinical Director of the Breast Oncology Program and Stuart B. Padnos Professor in Breast Cancer Research, University of Michigan Comprehensive Cancer Center

10:05 – 10:35 A.M.

Panel Discussion

10:35 – 10:50 A.M.

BREAK

10:50 A.M. – 12:55 P.M.

NEW MODELS FOR EVIDENCE GENERATION: APPLIED SCIENCE

 

Moderator: Elizabeth Mansfield, Director of the Personalized Medicine Staff, Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, U.S. Food and Drug Administration



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement